Dyadic International Selected for COVID-19 Vaccine Candidate Development

June 11, 2020

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Dyadic International, a biotechnology company based in Jupiter, FL, announced on June 10, 2020 that it has been selected by the Frederick National Laboratory for Cancer Research to develop its patented and proprietary C1 cell lines to produce COVID-19 vaccine candidates.

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, according to a company press release.

"We are proud that our C1 technology has the potential to support the Vaccine Research Center COVID-19 vaccine development program by engineering innovative high yield C1 fungal cell lines to rapidly produce candidate vaccines with increased immunogenicity and attractive manufacturing properties," said Mark Emalfarb, Dyadic's CEO, in the press release. "In addition, we are grateful to be able to also work together with the U[nited] S[tates], E[uropean] U[nion], Israel, and are in other discussions with governmental agencies, biotech/biopharma companies, and funding organizations to apply our industrially proven hyper-productive C1 gene-expression platform by helping to address the immediate coronavirus outbreak and be better prepared for future infectious diseases, pandemic, and epidemic outbreaks. We hope to turn this unfortunate situation into an opportunity to advance biopharmaceutical manufacturing to help speed development, lower the cost, and improve the performance of biologic vaccines and drugs, such as insulin, seasonal flu, and other vaccines and antibodies to make healthcare more accessible and affordable to patients globally."

Source: Dyadic